1 min read
SELLAS Prices $150 Million Stock Offering at $13 a Share
The offering covers 11.54 million common shares, with gross proceeds expected to total $150 million before discounts, commissions and other expenses.

SELLAS Life Sciences Group priced 11.54 million common shares at $13 each, setting expected gross proceeds at $150 million before underwriting discounts, commissions and offering expenses.
The pricing advances the public offering the company began Nov. 17. SELLAS previously reported positive results from its Phase 3 REGAL trial in patients with acute myeloid leukemia, including a statistically significant improvement in overall survival. The offering follows that earlier development and is separate from the trial results.
Read more about SELLAS’ launch of the $150 million stock offering.